Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

Oncologist

Volumn 15, Issue 5, 2010, Pages 457-465

  Tsoi, Daphne T ^a   Inoue, Miho ^b   Kelly, Catherine M ^a   Verma, Sunil ^a   Pritchard, Kathleen I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

21 gene assay; Cost effectiveness analysis; Early breast cancer; Oncotype DX

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

21 GENE ASSAY; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLASSIFICATION; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE SEQUENCE; DRUG SAFETY; EARLY CANCER; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE PAYMENT; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; TRANSITIONAL PROBABILITY; WILLINGNESS TO PAY THRESHOLD;

BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; GENES, NEOPLASM; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77952605337     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0275     Document Type: Article

References (30)

1. Canadian Cancer Society. Canadian Cancer Statistics, 2009. Available at www.cancer.ca, accessed August 5, 2009.
2. Jemal A, Siegal R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Invasive breast cancer, 2008. Available at http:// www.nccn.org/professionals/physician_gls/f_guidelines.asp, accessed December 10, 2008.
4. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320: 479-484.
5. Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr 1992;(11):105-116.
6. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-3365.
7. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
8. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.
9. BlueCross BlueShield Association. Gene expression profiling of breast cancer to select women for adjuvant chemotherapy, 2008. Available at www.bcbs.com/tec, accessed December 10, 2008.
10. Marchionni L, Wilson RF, Wolff AC et al. Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann Intern Med 2008;148:358-369.
11. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: CADTH, 2006. Available at http://www.acmts.ca/media/pdf/186_EconomicGuidelines_e.pdf, accessed December 10, 2008.
12. Bryant J. Toward a more rational selection of tailored adjuvant therapy:Data from the National Surgical Adjuvant Breast and Bowel Project; paper presented at St Gallen Breast Cancer Symposium, 2005. In Marchionni L et al. Ann Intern Med 2008;0:0000605-200803040-00208-E-208.
13. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160-168.
14. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001;(30):135-142.
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
16. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.
17. Skedgel C, Rayson D, Dewar R et al. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: Sequential tamoxifenexemestane and upfront anastrozole. Breast Cancer Res Treat 2007;101: 325-333.
18. Younis T, Rayson D, Dewar R et al. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol 2007;18:293-298.
19. Younis T, Rayson D, Sellon M et al. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat 2008;111:261-267.
20. Statistics Canada. Life Tables, Canada, Provinces and Territories, 2000-2002. Available at http://www.statcan.gc.ca, accessed December 10, 2008.
21. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
22. Earle CC, Chapman RH, Baker CS et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-3317.
23. Statistics Canada. Consumer Price Index, Health and Personal Care, by Province, 2008. Available at http://www.statcan.gc.ca, accessed December 10,2008.
24. Will BP, Berthelot JM, Le Petit C et al. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000;36:724-735.
25. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005; 11:313-324.
26. Kondo M, Hoshi SL, Ishiguro H et al. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat 2008;112:175-187.
27. Lyman GH, Cosler LE, Kuderer NM et al. Impact of a 21-gene RT-PCRassayontreatmentdecisionsinearly-stagebreastcancer:aneconomicanalysis based on prognostic and predictive validation studies. Cancer 2007; 109:1011-1018.
28. Oncotype DX, Genomic Health. www.genomichealth.com/OncotypeDX/Index.aspx.
29. Odette Cancer Centre pharmacy, 2008. Personal communication; information not publicly available.
30. Ontario Case Costing Initiative. Cost for treatment of sepsis, July 2008.Available at http://www.occp.com, accessed December 10, 2008.